5 Cannabis Sector Stocks – AC8, THC, MDC, CAN And CPH

5 Cannabis Sector Stocks - AC8, THC, MDC, CAN And CPH

The Global Cannabis Industry is growing at an exponential rate. To take the advantage of the growing demand of medicinal cannabis products with global legislative reforms, various Cannabis sector companies are now focusing on increasing their scale and on global expansion. Let’s take a quick look at some of the Cannabis sector stocks- [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

Creso Pharma Limited (ASX: CPH)

Medical Cannabis Company, Creso Pharma Limited (ASX: CPH) recently signed a strategic collaboration agreement with a Swiss-based company, Hempmate AG Switzerland. This collaboration will focus on the co-development and commercialization of Creso’s products in Europe, with first new products planned to be launched in Q2 2019. Recently on 13 February 2019, the company also announced a strategic collaboration with a subsidiary of Cannabis Doctors Australia Pty Ltd, Burleigh Heads Cannabis Pty Ltd. The collaboration with Burleigh Heads will be focused on the introduction of Creso’s medicinal cannabis products in Australia.

The company’s securities were recently reinstated to official quotation on 12 February 2019 after its trading pause on 1 February 2019. The company is currently in the middle of two possible material transactions which involves the spin out of Creso’s nutraceutical and other CBD assets and the acquisition by Creso of European based health food.

CPH’s shares last traded at $0.385 with a market capitalization of circa $51.49 million as on 14 February 2019.

Company Name In Collaboration with Area of Expansion
Creso Pharma Hempmate AG Europe
Creso Pharma Burleigh Heads Cannabis Pty Ltd Australia

AusCann Group Holdings Ltd (ASX: AC8)

AusCann Group Holdings Ltd (ASX: AC8) supplies high quality, cost-effective, cannabinoid medicines to its clients. Recently the company appointed Mr. Quentin Megson as the Joint Company Secretary, effective from 1 February 2019. AusCann Group Holdings Ltd has acquired a research and development (R&D) facility in Western Australia (WA). Research and development activities will help the company to produce high-quality products while ensuring cost-effectiveness for the patient. As at 31 December 2018, the company’s cash and cash equivalent stood at A$41.722 million.

In the past six months, the share price of the company HAS decreased by 48.54 percent as on 13 February 2019. AC8’s shares last traded at $0.440 with a market capitalization of circa $136 million as on 14 February 2019.

THC Global Group Ltd (ASX: THC)

Australia’s Leading Medicinal Cannabis Company, THC Global Group Ltd (ASX: THC) is having global commercial partners which are operating across four continents. The company has recently achieved a major milestone in its business plans for the expansion into New Zealand Medicinal Cannabis Market, by securing exclusive rights to import Endoca’s CBD products into New Zealand. The company is also exploring expansion possibilities in broader Asian region. The company possesses strong balance sheet with net equity of $28.3 million.

Meanwhile in the last six months, the share price of the company has increased by 16.16% as on 13 February 2019. THC’s shares last traded at $0.580 with a market capitalization of circa $73.18 million as on 14 February 2019.

Medlab Clinical Ltd (ASX: MDC)

Australian based medical life science company, Medlab Clinical (ASX: MDC) recently announced that a second round of recruitment is beginning for a clinical trial of NRGBiotic™. The clinical trial of NRGBiotic™ is focused on the treatment of depression. Recently the company signed an agreement with Australian Pharmaceutical Industries (API) to expand the potential distribution of Medlab products to more than 2100 independent pharmacies.

In the past six months, the share price has decreased by 12.09% as on 13 February 2019. MDC’s last shares traded at $0.385 with a market capitalization of circa $83.21 million as on 14 February 2019.

Cann Group Limited (ASX: CAN)

The developer of Medicinal cannabis products, Cann Group Limited (ASX: CAN) is having a three-year agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to investigate numerous opportunities across medicinal cannabis technologies. The company is focused on building a strong platform to generate sustainable profits and shareholder value over the long term. The company has secured Victorian Government (Department of Health and Human services) tender for supplying cannabis resin.

In the past six months, the share price of the company has decreased by 29.15 percent as on 13 February 2019. CAN’s shares last traded at $1.960 with a market capitalization of circa $268.23 million as on 14 February 2019.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report